mRNA vaccines are moving well beyond COVID — here's what's next

What just happened

Writing in MJA Insight+ this week, immunologist Gary Grohmann — a former TGA Director of Immunobiology and a board member of the Immunisation Coalition — and infectious diseases paediatrician Robert Booy lay out how comprehensively mRNA vaccine technology has moved beyond COVID-19. The platform that delivered more than 13 billion COVID-19 doses is now being applied to RSV, influenza, cytomegalovirus, HIV, malaria — and, most striking of all, cancer.

Some of this has already arrived in Australian clinical practice. Some is one or two years away. Some is a decade out. The piece is a useful map of where we actually are.

This lands at a moment when many people who followed the COVID-19 vaccine story closely are uncertain what to make of mRNA technology going forward — whether to trust it, what it can and can’t do, and whether the information they received during the pandemic prepared them well. The technology itself has not changed. But the context around it shifted in ways that are worth naming.

Both-and

RSV: the development that’s already here

The RSV vaccine is the clearest example of mRNA technology arriving in clinical practice in Australia. Grohmann and Booy confirm that both the FDA and TGA have registered mRNA RSV vaccines. For older Australians and people with chronic heart or lung conditions, RSV is not a trivial illness — it can cause severe lower respiratory tract disease, hospitalisation, and significant exacerbation of existing conditions. An effective RSV vaccine addresses a genuine unmet need.

RSV tends to be under-recognised as an adult health concern. Most people associate it with bronchiolitis in infants, which is accurate — RSV is a leading cause of infant hospitalisation. But in adults over 60 and in people with chronic disease, RSV causes substantial morbidity that often gets attributed to influenza or labelled “bad cold season.” A TGA-registered mRNA RSV vaccine changes the risk calculus for that group.

Whether ATAGI recommends RSV vaccination for specific adult groups, and whether it is funded on the National Immunisation Program, are the practical questions for Australian general practice right now.

Influenza: a genuine clinical upgrade in sight

The influenza data in the Grohmann and Booy piece is worth sitting with. Phase 3 trials showed mRNA influenza vaccines outperformed standard-dose licensed influenza vaccines in adults aged 50 and over. That is a meaningful finding.

The well-recognised limitation of standard-dose flu vaccines is that their effectiveness drops with age — the very population most at risk of serious influenza complications. High-dose and adjuvanted formulations have been attempts to address this. An mRNA influenza vaccine that demonstrates Phase 3 superiority over standard-dose vaccines in over-50s represents a different solution to the same problem, using a platform that can also be updated quickly when circulating strains drift.

If ATAGI moves to recommend mRNA influenza vaccines for older or higher-risk Australians, it would be the most practically significant shift in the annual immunisation conversation for general practice in some years.

Cancer: the most striking frontier

The most unexpected development for many readers will be how far personalised mRNA cancer vaccines have come. These are not preventive vaccines in the conventional public-health sense — they are therapeutic agents designed to train the immune system against a patient’s own tumour.

The mechanism: a cancer’s specific mutation profile is sequenced, and an mRNA vaccine is manufactured that presents tumour-specific antigens to the immune system, helping it recognise and attack cancer cells that express them. Early trials in melanoma have shown promising results, and studies are underway for pancreatic, lung, and ovarian cancers. These are not standard treatments yet — they remain within trial frameworks. But the trajectory is clear, and the mechanism is the same foundational technology proven at scale during COVID-19.

Pancreatic cancer in particular has historically had a very poor prognosis, in part because it resists standard chemotherapy. The early signals in personalised neoantigen vaccine trials for pancreatic cancer are being watched carefully by oncology.

The trust layer that technology alone can’t resolve

Grohmann and Booy name something directly uncomfortable: during the COVID-19 pandemic, different Australian states did not maintain consistent advice and guidelines, which — their words — “eroded public trust.” This deserves acknowledgement rather than a quick pivot.

The mRNA platform’s safety record is substantial: 13 billion COVID-19 doses, myocarditis predominantly in young males and typically mild with rapid recovery, strong and durable protection against severe disease. The technology has not become less safe. But for patients who experienced the communication inconsistencies, the policy whiplash, or the genuine harm of mandates that weren’t consistently applied, the technology and the institutional response to it became entangled in ways that don’t untangle automatically.

For GPs, separating those two things in consultation — the technology’s actual evidence base from the specific policy decisions made around it — may be one of the more important clinical communication tasks of the next few years. mRNA is now delivering across a broader clinical terrain. The conversations will keep coming.

My two cents

If you are forty-something and tracking your health actively, there are two near-term things worth knowing from this piece.

First, if you have asthma, chronic obstructive pulmonary disease, heart disease, or diabetes — or if you are over 60 — an RSV vaccination conversation with your GP is worth having now. RSV in adults with those conditions is underestimated in terms of its outcomes. The Australian Department of Health immunisation pages carry the current guidance on who should consider it.

Second, the mRNA flu story is one to watch before next winter. If the Phase 3 superiority data prompts ATAGI action, an updated recommendation could change the conversation at your annual flu vaccine appointment.

The cancer immunotherapy work is what to follow over the next decade. The early trial signals are genuine. But the path to standard treatment is long, and it runs through properly regulated trials — not supplements or private clinics.

Verdict: yes — the mRNA platform is already delivering clinical tools Australians can access now, and the flu and cancer developments are close enough to be worth understanding ahead of time.

---

Sources cited

1. All the Way with mRNA? Gary Grohmann and Robert Booy, MJA Insight+, 10 August 2026. https://insightplus.mja.com.au/2026/31/all-the-way-with-mrna
2. Respiratory syncytial virus (RSV) vaccines. Australian Government Department of Health and Aged Care. https://www.health.gov.au/topics/immunisation/vaccines/respiratory-syncytial-virus-rsv-vaccines
3. Australian Technical Advisory Group on Immunisation (ATAGI). Department of Health and Aged Care. https://www.health.gov.au/committees-and-groups/australian-technical-advisory-group-on-immunisation-atagi